Background: CS associated with NETs can have a negative impact on patients' QoL. Here, QoL data are evaluated from the SymNET study.
Methods:
The SymNET study was a large observational trial involving patients with a NET and a history of CS-related diarrhea (NCT01234168). Patients had been treated with LAN for >3 months. Patient-reported outcomes were assessed at a routine clinic visit. The primary endpoint was patient satisfaction with diarrhea control (PSD). Symptoms were evaluated using medical records. QoL was assessed using the EORTC QLQ-C30 and QLQ-GI.NET21 questionnaires, which assess functional dimensions (QLQ-C30; higher scores = better QoL) and symptoms (QLQ-C30 and QLQ-GI.NET21; lower scores = better QoL). Overall QoL was evaluated according to satisfaction with CS symptom control. (Table) ; in total, 70% of patients who were 'rather' or 'completely' satisfied had 'good', 'very good', or 'excellent' QoL.
Conclusion:
In a real-world setting, CS symptom control with LAN treatment translates into favorable levels of satisfaction among patients with NETs. Higher satisfaction levels were consistent with higher global health QoL scores. (14) 32 (16) 140 (70) 12 (26) 12 (26) 22 (48) 5 (28) 6 (33) 7 (39)
